Trial intelligence / Profile preview

Phase II study of compound Danshen injection for reducing radiotherapy adverse reactions in nasopharyngeal carcinoma

ChiCTR-TRC-13003841Phase 2Completed

Sponsor

General Hospital of Central Theater Command of the Chinese People's Liberation Army

Start

Mar 2014

Modality

Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules

Countries

1